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Introduction
Diffuse large B-cell lymphomas (DLBCL) are a heterogeneous group of non-Hodgkin lymphomas, of which ��% present at extranodal sites. Many extranodal DLBCL behave clinically essentially different from nodal DLBCL. A subset of extranodal DLBCL arises in immuneprivileged sites (IP-DLBCL), such as the central nervous system (CNS) or the testis. Among the extranodal DLBCL, testicular DLBCL stand out with a characteristic high relapse rate to the CNS and contralateral testis¹ and a very poor prognosis. In addition, patients with a lowrisk International Prognostic Index have a very poor outcome.² We previously described the loss of human leukocyte antigen (HLA) class I and II expression on tumor cells in more than ��% of the primary IP-DLBCL of the testis and CNS.³ -⁶
In both IP-DLBCL subtypes small homozygous deletions affected the HLA-DR and HLA-DQ genes, whereas larger hemizygous deletions affected the whole major histocompatibility complex (MHC) region, including class I and III regions, as well. The specificity of this downregulation in testicular DLBCL was confirmed in a recent immunohistochemical study on a large series of primary extranodal DLBCL presenting at various sites.⁷ In another recent study on predominantly primary nodal (non-IP) DLBCL, Rimsza et al.⁸ showed that loss of expression of HLA class II is highly discriminative for the clinical behavior of the disease and by far the most significant single prognostic factor. Furthermore, loss of HLA-DR expression correlated with a low number of CD�-positive T cells, suggesting that a presumed loss of tumor surveillance may have a negative effect on patient outcome.
To be�er understand the significance of downregulation of HLA class II expression in relation to the homozygous and hemizygous deletions, we studied a series of primary testicular DLBCL by gene expression microarray analysis a�er detailed characterization of the hemizygous and homozygous deletions. Additionally, we studied the gene expression patterns in testicular DLBCL with low and high HLA-DR mRNA expression. Here, we show that compared with normal B cells and primary nodal DLBCL, HLA-DR and HLA-DQ expression is dramatically downregulated in most testicular lymphomas. Whereas neither homozygous nor hemizygous deletions have any major additional effect on overall gene expression signatures, downregulation of HLA-DR is associated with a strong reduction of expression of many immune-associated genes and the number of infiltrating T cells.
Materials and methods

Tissue sample collection and selection
Frozen and paraffin-embedded lymphoma samples from �� primary testicular DLBCL and and immunodetection were performed as previously described.¹² In each DLBCL, signals were counted in ��� nuclei. As a control, each probe combination was hybridized on nuclei from � routine hyperplastic tonsil samples. Cutoff levels for the detection of hemizygous or homozygous loss were determined as the average percentage of nuclei harboring a deletion in these � tonsil samples plus thrice the SD. Cutoff levels for the presence of hemizygous deletions of MHC class I, III and II probes were thus set at ��%, ��% and ��% of nuclei harboring a deletion, respectively. Cutoff levels for homozygous deletions ranged from �% -�%.
Chromosome � array comparative genomic hybridization and data analysis
The chromosome � comparative genomic hybridization (CGH) array contained ��� genomic clones mapping to chromosome �, which were selected from the �-Mb BAC collec- 
Results
HLA expression and deletions in the HLA region
Primary testicular and primary nodal DLBCL were characterized for HLA protein expression on the tumor cells and for genomic deletions of the MHC region by interphase FISH.
Results are summarized in T���� �. Loss of expression of HLA-A/G and HLA-DR together with a high frequency of hemizygous and/or homozygous deletions in testicular DLBCL³ was confirmed in this extended series.
To determine the boundaries of the hemizygous deletions that o�en extend beyond the MHC region more in detail, �� testicular DLBCL for which genomic DNA was available were 
Class I homozygous
Testis (23) 3 (13) 3 (13) 16 (70) 5 (22) 13 (57) 11 (48) 2 (9) 11 (48) 2 (9) Nodal (10) 9 (90) 7 (70) 8 (80) 2 (20) 3 (30) 3 (30) 0 (0) 2 (20) 0 (0) Total (33) 12 (36) 10 (30) 24 (73) 7 (21) 16 (48) 14 (42) 2 (6) 13 (39) 2 (6) * Data are presented as percentage of nuclei harboring a deletion. Only percentages above cutoff levels are included; percentages below cutoff levels are indicated by -. † Indicates cases analyzed previously by Riemersma et al. 3 ‡These percentages are borderline significant. § For cases 24T, 25T and 26T only partial data was available; therefore, these are not included in the totals. Hemi: hemizygous; homo: homozygous; no del: no deletions; ND: not determined. were found with SAM (data not shown). Expression of classical HLA class II genes in both the deletion-positive and deletion-negative testicular DLBCL groups was � to � times lower than in the reference tonsil sample, confirming downregulation of these genes irrespective of deletions. There is a trend for the HLA-DQ and HLA-DR genes towards an even lower expression in cases with a homozygous deletion. Expression levels of non-classical HLA genes were equal to that in the reference tonsil sample. 
Global gene expression in relation to downregulation of HLA-DR mRNA expression
We analyzed global gene expression changes in testicular DLBCL in relation to HLA-DR mRNA expression (measured by averaging ratios of five HLA-DR clones). Six testicular lymphomas had expression levels similar to that of the tonsillar lymphoid tissue (ratio between �.�� and �.��), the other �� had lower expression levels varying from �.� to �.� times lower than the tonsillar reference sample (T���� �). Of note, all � cases without a deletion had a low expression. In a supervised analysis using SAM the global gene expression profiles of the � cases with the highest HLA-DR mRNA expression levels (�T, ��T, ��T, ��T, ��T and ��T) were compared with the profiles of the � cases with the lowest HLA-DR mRNA expression levels (�T, �T, �T, �T, ��T and ��T). Three hundred thirty-two clones were significantly (FDR≤�.���) That is, of the ��� unique genes and expressed sequence tags that are encoded by the ��� clones, �� (��%) were immune related. T���� � summarizes the most important findings. Of note, we found no significant correlation between HLA-DR mRNA and CD�� and/or CD�� mRNA expression, indicating that the differences are unlikely caused by differences in tumor content in these samples (T���� �A).
Because the previous results imply that the downregulation of expression of HLA-DR is a dominant phenomenon in many testicular DLBCL, we also intended to compare testicular DLBCL with and without HLA-DR protein expression on the tumor cells as assessed by immunohistochemistry. However, because only � cases were scored as positive, this analysis could not be performed. suggesting that no specific genes in this region are targeted.
Previous studies on predominantly nodal DLBCL have shown that loss of expression of HLA class II is an independent adverse prognostic factor.⁸ The present series of testicular DLBCL is not suitable for a meaningful correlative study on the relationship between HLA class II expression and clinical behavior because the cases were collected over a very long period of time and treatment was highly variable.
In conclusion, we found that loss of HLA class II mRNA expression in lymphoma cells and the surrounding infiltrate is associated with a significant change in global gene expression pa�erns reflecting a decrease in the immune response, which is paralleled by a decrease in the relative number of infiltrating reactive T cells. This effect is independent of the mechanism causing the downregulation of HLA-DR on the lymphoma cells.
